Radiation plus BCMA/CD3 bispecific antibody (CM336) for solitary bone plasmacytoma with mild marrow involvement
Official title: A Prospective Single-Arm Clinical Trial of Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
Run by Institute of Hematology & Blood Diseases Hospital, China · NCT07115667 · Data updated 2026-11-12
This will test whether adding the BCMA/CD3 bispecific antibody CM336 after radiotherapy can clear remaining cancer cells and lower the chance of progression in adults with solitary bone plasmacytoma and small amounts of bone marrow involvement.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 78 Years |
| Sex | All |
| Enrollment | 21 (estimated) |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Drugs / interventions | CAR-T, chimeric antigen receptor, cyclophosphamide, radiation |
| Locations | 1 site (Tianjin) |
| Status | Recruiting |
| Started | August 25, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2027 |
| Registry record updated | September 8, 2025 |
| Trial ID | NCT07115667 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically confirmed solitary bone plasmacytoma, less than 10% clonal plasma cells in bone marrow, ECOG 0–2, and no prior systemic anti-myeloma therapy are eligible.
✕Probably not a fit
Patients who have received prior systemic anti-plasma-cell therapies, have substantial marrow involvement, or have medical conditions making them unsuitable for the regimen are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-arm, single-center Phase 2 study treating adults with solitary bone plasmacytoma and <10% clonal plasma cells in the marrow. Participants receive local radiotherapy followed by a planned 12-cycle course of the BCMA/CD3 bispecific antibody CM336. The study monitors safety, tolerability, and measures depth of disease clearance and markers of progression. The goal is to determine whether the addition of CM336 can eradicate residual clonal cells and reduce progression to multiple myeloma.
Why it matters
Potential benefit: If successful, this approach could reduce progression to multiple myeloma and improve long-term disease control for high-risk solitary bone plasmacytoma patients.
How similar studies have gone: BCMA-targeted bispecific antibodies have shown promising activity in relapsed/refractory multiple myeloma, but combining a BCMA/CD3 bispecific with radiotherapy for solitary bone plasmacytoma is a novel approach with limited prior data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years old * Histologically confirmed SBP with \<10% clonal plasma cells in marrow * ECOG ≤ 2 * No prior anti-myeloma therapy. Previous local radiotherapy for SBP is not an exclusion criterion. * Meets laboratory and imaging criteria Exclusion Criteria: 1. Patients who have previously received anti-plasma cell therapy, including melphalan, cyclophosphamide, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, or chimeric antigen receptor T-cell (CAR-T) therapy. 2. Any condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.
Where it's running
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China Recruiting
Study contacts
- Study coordinator: Gang An, MD
- Email: angang@ihcams.ac.cn
- Phone: 13502181109
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GPRC5D-targeted PET/CT imaging in plasma cell disorders
This study tests a new GPRC5D-targeted PET/CT imaging method in adults with plasma cell disorders to see if it detects disease better or differently than standard imaging.
-
Identifying precancerous multiple myeloma in African American adults
This study is testing a way to find early signs of multiple myeloma in Black and African American adults aged 30 and older to help catch it sooner and improve their health outcomes.
-
Evaluating gut microbiome in patients with POEMS syndrome and other plasma cell disorders
This study looks at the gut bacteria in people with POEMS syndrome and other plasma cell disorders to see how it differs from healthy individuals and how it might change between active disease and remission.
-
Combining SBRT and Lenalidomide for treating Solitary Plasmacytoma
This study is testing whether combining a targeted radiation treatment with a medication can help people with a rare type of tumor called solitary plasmacytoma respond better to treatment and live longer without the disease progressing.
-
Quadruplet induction plus autologous transplant followed by teclistamab maintenance for plasma cell leukemia
This phase 2 trial tests whether adding teclistamab as consolidation after autologous stem cell transplant improves overall survival for patients with plasma cell leukemia compared with the standard D-KRd consolidation.
-
Autologous stem‑cell transplant plus BCMA CAR‑T for ultra‑high‑risk multiple myeloma
This test combines an autologous stem‑cell transplant with BCMA CAR‑T therapy to see if it helps adults (18–70) with ultra‑high‑risk multiple myeloma who are eligible for transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.